Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Study Purpose

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms:

  • - GPC-100 in combination with propranolol; or.
  • - GPC-100 in combination with propranolol and G-CSF.
To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian Optimal Phase II (BOP2) design to enroll patients for each arm. All patients will receive 30 mg propranolol (3 10 mg tablets) twice daily at 8:30 AM (1 hr) and 4:00 PM (1 hr) local time from Days 1 to 8 (and on Day 9, if applicable). Patients will administer the first dose of propranolol onsite on Day 1. Patients will be provided with doses of propranolol for administration at time points when they are not otherwise required to be onsite. Sites should contact patients via telephone to confirm propranolol administration for doses administered outside of clinic.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Male or female, greater than or equal to18 years of age; 2. Patients with diagnosis of MM per the International Myeloma Working Group criteria ; 3. Eligible for ASCT at the Investigator's discretion; 4. >4 weeks since completion of last cycle of chemotherapy prior to Day 1; 5. Patient must be on first or second complete response or partial response; 6. Eastern Cooperative Oncology Group performance status of 0 or 1 ; 7. ANC > 1.0 x 109/L on Screening laboratory assessments; 8. Platelet count >100 x109/L on Screening laboratory assessments; 9. Creatinine clearance >30 ml/min, as calculated according to the Cockcroft-Gault formula; 10. Aspartate aminotransferase and alanine aminotransferase <2 x upper limit of normal (ULN) and total bilirubin <1.5 x ULN on Screening laboratory assessments; 11. Adequate cardiac (left ventricular ejection fraction [LVEF] >50%) and pulmonary function (room air O2 saturation value >92%); 12. For females, 1 of the following criteria must be fulfilled: 1. At least 1 year postmenopausal; or. 2. Surgically sterile, or willing to use a double-barrier method of contraception (eg, intrauterine device plus condom, spermicidal gel plus condom) from Day 1 until 28 days after the last dose of GPC-100. 13. Males must be willing to use a reliable form of contraception (eg, use of a condom or a partner fulfilling the above criteria) from Day 1 until 28 days after the last dose of GPC-100; and. 14. Patients must be willing and able to provide signed informed consent.

Exclusion Criteria:

Patients must be excluded if they meet any of the following criteria: 1. >25% of BM irradiated within 5 years prior to Day 1; 2. Induction therapy cycles administered prior to stem cell mobilization, per institution standards; 3. Patients who have undergone previous stem cell transplant; 4. Receipt of G-CSF within 2 weeks prior to Day 1; 5. History of another malignancy except for the following: 1. Adequately treated local basal cell or squamous cell carcinoma of the skin; 2. Adequately treated carcinoma in situ of the cervix without evidence of disease; 3. Adequately treated papillary, noninvasive bladder cancer; or. 4. Low-grade prostate cancer that is on active surveillance and not expected to clinically progress over 2 years. 6. Patients who are on BBs and unable to switch therapy; Note: Patients on BBs who are able to switch therapy will undergo a gradual tapering of their current BB under the guidance of the Investigator. At the Investigator's discretion, the initial days of propranolol administration may be permitted to overlap with the final days of tapering of the previous BB. 7. Patients with severe asthma who require beta agonist therapy; 8. History of poor and uncontrolled cardiovascular or pulmonary disease such as myocardial infarction, cardiac arrhythmias, transient ischemic attack, congestive heart failure (New York Heart Association heart failure class >2), stroke, unexplained syncope, or chronic obstructive pulmonary disease; 9. History of long QT syndrome or torsade de pointes; 10. Patients with a QTcF >470 msec or PR interval >280 msec on Screening 12-lead electrocardiogram (ECG); 11. Active infection requiring treatment in the 7 days before Day 1; 12. Positive polymerase chain reaction test from nasal specimen for SARS-CoV-2 within 7 days prior to Day 1; 13. Pregnant or breastfeeding; 14. Known psychiatric or substance abuse disorder that would interfere with Protocol compliance; 15. Receipt of any other investigational drug or device within 1 month before Day 1; or. 16. Receipt of prior treatment with CXCR4 inhibitor for stem cell collection. -

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05561751
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

GPCR Therapeutics, Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Not yet recruiting
Countries
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Additional Details

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arms:

  • - GPC-100 in combination with propranolol; or.
  • - GPC-100 in combination with propranolol and G-CSF.
To characterize the safety and clinical activity of GPC-100, the study will employ a Bayesian Optimal Phase II (BOP2) design to enroll patients for each arm. All patients will receive 30 mg propranolol (3 10 mg tablets) twice daily at 8:30 AM (1 hr) and 4:00 PM (1 hr) local time from Days 1 to 8 (and on Day 9, if applicable). Patients will administer the first dose of propranolol onsite on Day 1. Patients will be provided with doses of propranolol for administration at time points when they are not otherwise required to be onsite. Sites should contact patients via telephone to confirm propranolol administration for doses administered outside of clinic. Only patients randomized to the treatment arm receiving GPC-100 in combination with propranolol and G-CSF will receive SC injections of 10 g/kg/day G-CSF at 4:00 PM (1 hr) local time on Days 3 to 7. Patients in this arm will receive G-CSF injections on Day 8 at 4:00 PM (1 hr) local time only if they will undergo the optional third day of mobilization/collection (Day 9) at the Investigator's discretion. On Days 7 and 8 (and on Day 9, if applicable), the patient will receive a morning 30 mg propranolol dose (3 10 mg tablets) followed immediately by a 3.14 mg/kg dose of GPC-100 free base (active ingredient) and will start collection of CD34+ stem cells via leukapheresis.

Arms & Interventions

Arms

Experimental: GPC-100 in combination with propranolol;

Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol; or

Experimental: GPC-100 in combination with propranolol and G-CSF

Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will be randomized in a 1:1 ratio to the following treatment arm: • GPC-100 in combination with propranolol and G-CSF.

Interventions

Drug: - GPC-100

GPC-100 is to be administered at a dose of 3.14 mg/kg GPC-100 free base via IV infusion. The corresponding volume of the reconstituted GPC-100 solution calculated based on the patient weight will be administered via IV infusion over 15 min

Drug: - Propranolol

propranolol

Drug: - G-CSF

G-CSF

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

For additional contact information, you can also visit the trial on clinicaltrials.gov.